Mumbai, India (PressExposure) February 24, 2009 -- Conference on Vaccine Manufacturing
Date and Venue: 11th - 12th May 2009, BSG Conference Centre, London, UK
Vaccine development, supported by infusions of public and private venture capital, is re-entering a golden age as one of the fastest growing sectors in the life-sciences industry. The global vaccines market, worth $25bn in 2009, is expected to sustain double-digit growth over the next 15 years, rising to over $100bn by 2024.
Over the past two centuries, immunisation programs have led to the elimination and/or control of several different infectious diseases including smallpox, polio, measles, mumps and rubella. More recently, the past 30 years have seen significant changes both in the number of businesses involved in vaccine manufacture and the production systems used. These include fewer companies, higher costs, and a shift from egg-based to cell-based processes, to reduce allergenicity, optimise quality and increase output.
While more vaccines are now available than ever before, they have long presented special issues for producers, particularly regarding scale-up, affordability, and change of pace. Enduring challenges include ensuring good laboratory and manufacturing process, maintenance of product stability, and preparing a 100% safe and effective product. With time-to-market and flexibility increasingly important to improve cost-effectiveness, producers are becoming increasingly cognisant of the latest technologies to simplify development and manufacturing.
While the market remains dominated by a select group of key players, technology transfer is increasing between small biotech companies and big pharma. More significantly, with emerging markets set to dominate vaccine manufacturing by 2023, globalisation is being taken seriously as the quickest way to develop a product and increase market access.
For More Information kindly visit : [http://www.bharatbook.com/seminars/Conference-Vaccine-Manufacturing.asp]